|
 |
Jeremy R. Degenhart
Principal
St. Louis
Mr. Degenhart joined Advantage Capital Partners in 2001. As a Principal in the St. Louis office, Mr. Degenhart has a wide range of responsibilities including screening deal flow, conducting due diligence, negotiating transactions, managing existing investments, and developing exit opportunities. In addition to portfolio management, Mr. Degenhart has responsibility for developing and analyzing new fundraising structures, and facilitating their implementation.
Mr. Degenhart serves on the Board of Directors of Veran Medical Technologies; Quick Study Radiology; Waste Remedies; Carbolytic Materials Company; and Sunflower Food & Spice. He also leads Advantage Capital's investment in Kereos and The Lawrence Group. Previous investments led by Mr. Degenhart include Stereotaxis, which held an initial public offering in 2004 (NASDAQ:STXS); and DataTrade, which sold to Goldleaf Financial in 2007 (NASDAQ:GFSI).
Prior to joining Advantage Capital, Mr. Degenhart worked as an analyst for Wydown Capital, a boutique investment bank. While at Wydown, Mr. Degenhart served as the analyst for proposed placements and acquisitions totaling over $100 million.
Mr. Degenhart was the valedictorian of his undergraduate class at the John M. Olin Business School at Washington University in St. Louis, receiving a BSBA in finance, economics, and accounting in May 2000. Mr. Degenhart also serves on the Board of Directors of the InvestMidwest Venture Capital Forum and lectures on venture capital and private equity as an adjunct faculty member of the Olin Business School.
|
|
Back to list
|
|
|
|
